Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

See Also

Health Health / Illness, Injury & Treatments Health / Medical Practice Science & Technology / Biology & Life Sciences

Current Medical Articles

Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Chemistry World February 2012	Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
Chemistry World January 23, 2012 James Urquhart	Simple One Stop Shop for Difluoromethylation A new process developed by researchers opens the way for adding difluoromethyl (CF 2H) groups to drugs and agrochemicals in order to enhance their properties.
Chemistry World January 20, 2012 Sarah Houlton	Takeda slashes 10% of its workforce This represents about 10% of its workforce, and the cuts will be made in research, commercial and admin sections of the business.
The Motley Fool January 20, 2012 Brian Orelli	19 Clinical Trials Aren't Enough The FDA rejects Bristol-Myers and AstraZeneca's dapagliflozin.
The Motley Fool January 20, 2012 Seth Jayson	Intuitive Surgical Beats Up on Analysts Yet Again For the quarter ended Dec. 31, Intuitive Surgical beat expectations on revenues and beat expectations on earnings per share.
The Motley Fool January 20, 2012 Seth Jayson	ZOLL Medical Beats Up on Analysts Yet Again For the quarter ended Jan. 1, ZOLL Medical met expectations on revenue and beat expectations on earnings per share.
The Motley Fool January 20, 2012 Seth Jayson	UnitedHealth Group Beats Estimates Yet Again For the quarter ended Dec. 31, UnitedHealth Group met expectations on revenues and crushed expectations on earnings per share.
The Motley Fool January 20, 2012 Dan Caplinger	Can Geron Recover in 2012? Let's look at this year's prospects for this company.
The Motley Fool January 19, 2012 Sean Williams	No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear.
The Motley Fool January 19, 2012 Brian Orelli	New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go.
The Motley Fool January 19, 2012 Anders Bylund	Can This Moat Still Stave Off Invading Hordes? A closer look at Intuitive Surgical's competition only confirms the thesis: this moat is safe as houses.
The Motley Fool January 18, 2012 Brian Orelli	2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial.
The Motley Fool January 18, 2012 Sean Williams	This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount.
The Motley Fool January 18, 2012 Sean Williams	Are These 2 Medical Device Makers Takeover Targets? Could these two medical device makers put themselves up for sale in 2012?
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool January 17, 2012 Dan Caplinger	What 2012 Has in Store for Star Scientific Let's look at this year's prospects for this company.
Chemistry World January 11, 2012 Andrew Turley	BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection.
IndustryWeek January 11, 2012	Northeast Indiana's Instrumental Assets Medical-device manufacturers are finding the 10-county Northeast Indiana region a prime location with a skilled workforce.
IndustryWeek January 11, 2012	Life Technologies: IW Best Plants Profile 2011 This plant transformation created a true manufacturing environment in a science-based culture and major revenue wins.
Fast Company January 9, 2012 Adam Bluestein	As Smartphones Get Smarter, You May Get Healthier: How mHealth Can Bring Cheaper Health Care To All Smartphones and tablets are transforming the future of health care. Can we really trust them to save lives?
Pharmaceutical Executive January 1, 2012 Julian Upton	iPad Apps: Are You Content with your Content? Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
Pharmaceutical Executive January 1, 2012 Mason Tenaglia	Letting the Facts Get in the Way An empirical defense of coupons and copay offset programs.
Pharmaceutical Executive January 1, 2012	Compliance: Getting Those Ducks in a Row Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive January 1, 2012 William Looney	The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition.
Pharmaceutical Executive January 1, 2012 Elys Roberts & Sarah Phillips	The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Pharmaceutical Executive January 1, 2012 Ben Comer	Top Medical Innovations 2012 A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.
Pharmaceutical Executive January 1, 2012	Here's to a Happier New Year? A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
Pharmaceutical Executive January 1, 2012 Christopher J. Piazza	Essential Questions for Essential Benefits A key consideration under the Affordable Care Act is how states select plans for drug coverage.
Pharmaceutical Executive January 1, 2012 Bill Drummy	Scared to Death The pharma industry's risk-aversion is risking its survival. Where did the courage to innovate go?
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
Chemistry World January 2012	Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
Chemistry World January 2012	Rising interest in compound bank David Fox argues for the creation of a centralized repository for small molecules to harness research efforts in drug discovery
Information Age December 8, 2011 Hal Hodson	Secret identities The government plans to share anonymised NHS data with businesses, but can patients' identities really be disguised?
Chemistry World December 22, 2011 Sarah Houlton	Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition.
There are 8353 old articles available for this category.